Methods for detecting RNA modifications with DNA nanoswitches
This technology uses DNA nanoswitches to directly and specifically detect RNA modifications, allowing simultaneous identification of multiple modifications in their natural sequence context for research, diagnostics, and drug discovery applications.
Background:
RNA modifications, such as methylation, play critical roles in gene regulation, cellular...
Published: 3/9/2026
|
Inventor(s): Kenneth Halvorsen, Iranna Todkari, Andrew Hayden
Keywords(s): Technologies
Category(s): Campus > University at Albany, Technology Classifications > Diagnostics, Technology Classifications > Biomedical Science and Engineering, Technology Classifications > Drug Design and Synthesis
|
Development of SelU Inhibitors as New Antibiotics
Scientists discovered that special chemical modifications on bacterial tRNA help control protein production and stress responses. They have also developed novel compounds that take advantage of this mechanism to produce antibiotic effects.
Background:
The field of epitranscriptomics focuses on the chemical modifications of RNA molecules, which are...
Published: 3/5/2026
|
Inventor(s): Jia Sheng, Thomas Begley
Keywords(s): antibiotics, inhibitors, Technologies
Category(s): Campus > University at Albany, Technology Classifications > Drug Design and Synthesis
|
Sterylglucosidase Inhibitors as Antifungal Agents
050-9346 Sterylglucosidase Inhibitors as Antifungal Agents
Novel antifungal compounds that function as substrate-mimicking inhibitors of sterylglucosidase for antifungal medication and therapeutics
Background:
Invasive fungal infections, such as life-threatening meningoencephalitis caused by Cryptococcus neoformans and severe pulmonary aspergillosis...
Published: 2/19/2026
|
Inventor(s): Iwao Ojima, Maurizio Del Poeta, Michael Airola, Nivea Pereira de Sa, SeungYoun Shin, Kalani Jayanetti, Dominick Rendina, Ananya Shibana Thennarasu
Keywords(s):
Category(s): Technology Classifications > Drug Design and Synthesis, Campus > Stony Brook University, Campus
|
Macrocycle-Based Chelators for Room Temperature Chelation of Radioactive Isotopes
050-9235 Macrocycle-Based Chelators for Room Temperature Chelation of Radioactive Isotopes
Ternary complexes that produce robust radiopharmaceuticals with a high radiochemical yield and specific activity for enhanced radiolabeling
Background:
The management of various cancers, particularly prostate cancer, increasingly relies on targeted radiotherapeutics...
Published: 2/13/2026
|
Inventor(s): Eszter Boros, Brett Vaughn, Jennifer Whetter
Keywords(s):
Category(s): Technology Classifications > Drug Design and Synthesis, Technology Classifications > Medical Imaging, Campus > Stony Brook University
|
LpxC Inhibitors for Gram-Negative Infections
Treatment of multidrug-resistant bacterial infections with LpxC inhibitors for reduced drug resistance and improved safety profiles
RSS.HDBackground> Background: <
Infection by Gram‑negative bacteria such as Pseudomonas aeruginosa, β‑lactamase producing (ESBL) Enterobacteriaceae, and Acinetobacter baumannii is a major health problem, especially...
Published: 7/25/2025
|
Inventor(s): Peter Tonge, Fereidoon Daryaee, Sneha Basak
Keywords(s):
Category(s): Campus > Stony Brook University, Technology Classifications > Drug Design and Synthesis
|
Design and Synthesis of Novel Methotrexate Conjugated MicroRNA Mimic Modified with 5-Fluorouracil and/or Gemcitabine as a Platform Technology for Cancer Treatment
A platform for modifying miRNAs and using the modified miRNAs as novel cancer therapeutics.
RSS.HDBackground> Background: <
Resistance to chemotherapy can be a highly complex issue, with epigenetic alterations playing a key role in tumorigenesis and chemotherapy resistance. The failure to treat several advanced solid tumors can be often attributed...
Published: 7/25/2025
|
Inventor(s): Jingfang Ju, Iwao Ojima, John Yuen, Lei Chen
Keywords(s):
Category(s): Campus > Stony Brook University, Technology Classifications > Drug Design and Synthesis
|
Concerted, Selective Radiometallation and Photo-triggered Release of Ready-to-Inject Radiopharmaceuticals from the Solid Phase
Solid Phase Radiometallation Photorelease method for the preparation of injectable radiopharmaceuticals
RSS.HDBackground> Background: <
Radiopharmaceuticals are agents which enable non-invasive patient diagnosis and personalized therapeutic intervention strategies. Radionuclides used in nuclear medicine applications must be purified after nuclear...
Published: 2/4/2025
|
Inventor(s): Eszter Boros, Dariusz Śmiłowicz
Keywords(s):
Category(s): Technology Classifications > Diagnostics, Campus > Stony Brook University, Technology Classifications > Drug Design and Synthesis
|
6-azasteroids with unique activity in mycobacteria
The compound functions as potentiators of several anti-tuberculosis drugs
RSS.HDBackground> Background: <
One third of the world’s population is infected with tuberculosis (TB). In 2014, there were 1.5 million TB related deaths. There are drugs to combat the bacteria by attacking the bacteria directly. The current recommended treatment...
Published: 5/14/2025
|
Inventor(s): Nicole Sampson, Joshua Werman, Tianao Yuan
Keywords(s):
Category(s): Technology Classifications, Campus > Stony Brook University, Technology Classifications > Drug Design and Synthesis
|
Metal-mediated, Autolytic Amide Bond Cleavage for the Selective, Metal-Complexation Catalyzed, Controlled Release of Metallodrugs
Autolytic, metal complex-mediated amide bond cleavage for prodrug activation and synthesis of metallodrugs
RSS.HDBackground> Background: <
Clinically viable prodrugs release activated drug molecules at the site of interest, requiring close spatiotemporal control. Bond cleavage strategies for the release of the activated drug often incorporate...
Published: 7/28/2025
|
Inventor(s): Eszter Boros, Dariusz Śmiłowicz
Keywords(s):
Category(s): Technology Classifications > Drug Delivery, Campus, Campus > Stony Brook University, Technology Classifications > Drug Design and Synthesis
|
Benzodiazepinone-derived Inhibitors of EGFR and HER2
A class of benzodiazepinone-derived molecules, inhibitors of both triple mutant EGFR and HER2, for cancer therapeutics or biochemical research tools.
Background:
Inhibition of epithelial growth factor receptor (EGFR) as a non-small cell lung cancer (NSCLC) therapeutic is not a new concept, but 75% of patients die within five years of diagnosis. As...
Published: 2/19/2026
|
Inventor(s): David Heppner, Stefan Laufer, Florian Wittlinger, Blessing Ogboo, Calvin Pham, Alexander Rasch
Keywords(s): Featured, Technologies
Category(s): Campus > University at Buffalo, Technology Classifications > Therapeutics and Vaccines, Technology Classifications > Materials and Chemicals, Technology Classifications > Drug Design and Synthesis, Technology Classifications > Research Tools and Reagents
|